Indications and uses
helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
empty entire contents of packet onto tongue and swallow for best taste, do not chew granules do not take more than 6 doses in any 24-hour period Age Dose adults and children 12 years and over 2 to 4 packets every 4 hours children 6 years to under 12 years 1 to 2 packets every 4 hours children 4 years to under 6 years 1 packet every 4 hours children under 4 years do not use
each packet contains: magnesium 6 mg and sodium 3 mg phenylketonurics : contains phenylalanine 1 mg per packet store between 20-25°C (68-77°F) tamper evident: do not use if carton is open or if packets are torn or open
Drug Facts
Guaifenesin 100 mg
Expectorant
helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. These could be signs of a serious illness.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
| Age | Dose |
|---|---|
| adults and children 12 years and over | 2 to 4 packets every 4 hours |
| children 6 years to under 12 years | 1 to 2 packets every 4 hours |
| children 4 years to under 6 years | 1 packet every 4 hours |
| children under 4 years | do not use |
aspartame, banana flavor, butylated methacrylate copolymer, carbomer homopolymer type A, carboxymethylcellulose sodium, magnesium stearate, microcrystalline cellulose, povidone, sodium bicarbonate, sorbitol, stearic acid, talc, triethyl citrate, tutti-frutti flavor
1-866-682-4639
You may also report side effects to this phone number.
Dist. by: Reckitt Benckiser
Parsippany, NJ 07054-0224
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 63824-254-12 | 2023-08-31 | C162847 | 48780-1 | 9d75b9d0-99f1-f424-e053-dadaa90a57ce | Children's Mucinex® Mini-Melts™ Chest Congestion |
| 63824-254-18 | 2023-08-31 | C162847 | 48780-1 | 9d75b9d0-99f1-f424-e053-dadaa90a57ce | Children's Mucinex® Mini-Melts™ Chest Congestion |
| 63824-254-12 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-99f1-f424-e053-dadaa90a57ce | Children's Mucinex® Mini-Melts™ Chest Congestion |
| 63824-254-18 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-99f1-f424-e053-dadaa90a57ce | Children's Mucinex® Mini-Melts™ Chest Congestion |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63824-254-12 | EA - Each | 63824-254 | c02fa0fc-637f-4539-b5a1-f95984089064 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Guaifenesin | ACTIVE INGREDIENT | 495W7451VQ | 2 | |
| Guaifenesin | ACTIVE MOIETY | 495W7451VQ | 2 | |
| aspartame | INACTIVE INGREDIENT | Z0H242BBR1 | 2 | |
| carbomer homopolymer type A (allyl pentaerythritol crosslinked) | INACTIVE INGREDIENT | F68VH75CJC | 2 | |
| carboxymethylcellulose sodium | INACTIVE INGREDIENT | K679OBS311 | 2 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| povidone | INACTIVE INGREDIENT | FZ989GH94E | 2 | |
| sodium bicarbonate | INACTIVE INGREDIENT | 8MDF5V39QO | 2 | |
| sorbitol | INACTIVE INGREDIENT | 506T60A25R | 2 | |
| stearic acid | INACTIVE INGREDIENT | 4ELV7Z65AP | 2 | |
| talc | INACTIVE INGREDIENT | 7SEV7J4R1U | 2 | |
| triethyl citrate | INACTIVE INGREDIENT | 8Z96QXD6UM | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 63824-254 | 63824-254-12, 63824-254-02, 63824-254-18 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | SOLUTION/ DROPS / OPHTHALMIC | 2 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / ORAL | 360 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION / NASAL | 25 mg/1ml | ||
| triethyl citrate | TRIETHYL CITRATE | 8Z96QXD6UM | TABLET / ORAL | 52 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION / ORAL | 29268 mg | ||
| sorbitol | SORBITOL | 506T60A25R | GUM, CHEWING / ORAL | 6168 mg | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | CAPSULE, EXTENDED RELEASE / ORAL | 64 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET, DELAYED RELEASE PARTICLES / ORAL | 56 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | FILM / BUCCAL | 18 mg | ||
| aspartame | ASPARTAME | Z0H242BBR1 | GRANULE, FOR SUSPENSION / ORAL | 420 mg | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | CAPSULE / ORAL | 90 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / RECTAL | 32.4 mg | ||
| povidone | POVIDONE | FZ989GH94E | DROPS / ORAL | NA | ||
| aspartame | ASPARTAME | Z0H242BBR1 | SUSPENSION / ORAL | 23 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET, DELAYED RELEASE / ORAL | 349 mg | ||
| talc | TALC | 7SEV7J4R1U | OINTMENT / TOPICAL | 74.6 %w/w | ||
| aspartame | ASPARTAME | Z0H242BBR1 | LOZENGE / ORAL | 136 mg | ||
| povidone | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| sorbitol | SORBITOL | 506T60A25R | PASTE / DENTAL | 14.6 %w/w | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| triethyl citrate | TRIETHYL CITRATE | 8Z96QXD6UM | SUSPENSION / ORAL | 71 mg | ||
| povidone | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | LOZENGE / ORAL | 100 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | GRANULE / ORAL | NA | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GRANULE, EFFERVESCENT / ORAL | 267 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, FILM COATED / ORAL | 86 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / SUBLINGUAL | 32.4 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | TABLET, EXTENDED RELEASE / ORAL | 933 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| aspartame | ASPARTAME | Z0H242BBR1 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 18 mg | ||
| aspartame | ASPARTAME | Z0H242BBR1 | FILM, EXTENDED RELEASE / BUCCAL | 1 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | INJECTION, SUSPENSION / INTRAMUSCULAR | 30 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SOLUTION / ORAL | 690 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| talc | TALC | 7SEV7J4R1U | ELIXIR / ORAL | 4.5 mg/5ml | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | INJECTION / INTRA-ARTICULAR | 25 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | INJECTION / INTRASYNOVIAL | 0.1 %w/v | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | SOLUTION / OPHTHALMIC | 1 mg | ||
| sorbitol | SORBITOL | 506T60A25R | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / BUCCAL | 42 mg | ||
| carbomer homopolymer type A (allyl pentaerythritol crosslinked) | CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | F68VH75CJC | CAPSULE / ORAL | 32 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE / ORAL | 29520 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg | ||
| povidone | POVIDONE | FZ989GH94E | IMPLANT / SUBCUTANEOUS | 6 mg | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | TABLET, DELAYED RELEASE / ORAL | 80 mg | ||
| carboxymethylcellulose sodium | CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | SYRUP / ORAL | 26.5 mg | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / VAGINAL | 4 %w/w | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / SUBLINGUAL | 43.2 mg | ||
| aspartame | ASPARTAME | Z0H242BBR1 | POWDER, FOR SUSPENSION / ORAL | 420 mg | ||
| povidone | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| talc | TALC | 7SEV7J4R1U | CAPSULE, COATED / ORAL | 87 mg | ||
| sorbitol | SORBITOL | 506T60A25R | LIQUID / TOPICAL | 1 %w/w | ||
| aspartame | ASPARTAME | Z0H242BBR1 | SYRUP / ORAL | 0.63 mg/5ml |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| fbd15264-3bd6-015a-e053-6294a90abc6a | fd8a69aa-eb75-4e7a-8b6e-3361f810c578 | 2023-05-16 | Warnings | fbd15264-3bd6-015a-e053-6294a90abc6a fd8a69aa-eb75-4e7a-8b6e-3361f810c578 |
Adverse event summaries are temporarily unavailable. Other product information remains available.